Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Of the eleven ELISAs applied to the ‘discovery’ cohort (n = 47, one sample was unavailable for validation), six (NrCAM, YKL-40, chromogranin A, carnosinase I, transthyretin, cystatin C) showed statistically significant or near-significant differences between CDR 0 and CDR 1 groups ( Figure 4 ); five others (PEDF, beta-2 microglobulin, clusterin/apoJ, ceruloplasmin, apoE) did not.

also in 2,306 other papers